Dendritic Cell Therapy in India: A Complete Patient Guide (2026)

If you have been researching immunotherapy for cancer, you have likely come across the term “Dendritic Cell Therapy.” It sounds technical — because it is. But the principle behind it is elegantly logical, and understanding it may well change how you think about cancer treatment.

Denvax has been at the forefront of Dendritic Cell Therapy in India for over a decade. We were among the first to bring this treatment to Indian patients, and we have refined our protocols continuously as the science has advanced. This guide explains exactly what Dendritic Cell Therapy is, how we deliver it, who it is appropriate for, and what patients can expect.

What Is Dendritic Cell Therapy?

To understand Dendritic Cell Therapy, you first need to understand what dendritic cells are and why they matter.

Your immune system is remarkably sophisticated. It has specialised cells for different roles: T-cells that attack threats, B-cells that produce antibodies, natural killer cells that patrol for abnormalities. But none of these soldiers can act without orders. They need to know what to attack.

Dendritic cells are the intelligence commanders of your immune system. Their job is to scan the body, identify foreign or abnormal material, break it down, and then present that information to T-cells with a clear instruction: “Find cells that look like this and destroy them.”

In a healthy body, this system works continuously. Your immune system identifies and eliminates abnormal cells — including early cancer cells — all the time. Cancer becomes a problem when it evolves mechanisms to evade this surveillance. Cancer cells can produce proteins that essentially wave a “friendly flag” to the immune system, or they can suppress the dendritic cells’ ability to process and present information correctly.

Dendritic Cell Therapy corrects this failure directly. Here is how:

1. We extract a small amount of your blood
2. We isolate the dendritic cell precursors (monocytes)
3. In our laboratory, we mature these cells into fully active dendritic cells
4. We expose them to antigens specific to your cancer — tumour material that identifies your cancer’s unique markers
5. The educated dendritic cells are then infused back into your body
6. Once inside, they instruct your T-cells precisely what your cancer looks like
7. Your immune system mounts a targeted, personalised attack against the cancer

The crucial difference between this and chemotherapy is intent. Chemotherapy is a broad intervention that kills rapidly dividing cells — cancer cells and healthy cells alike. Dendritic Cell Therapy is a precision intervention. It teaches your own body to distinguish between cancer cells and healthy cells, and to attack only the cancer.

Why Personalisation Matters?

No two cancers are identical — even the same type of cancer in two different patients will have different mutations, different surface markers, and different behaviours. This is why generic treatments often produce inconsistent results.

Dendritic Cell Therapy is, by definition, personalised. The dendritic cells we return to your body have been specifically educated using material from your tumour. They are not taught to recognise “lung cancer in general” — they are taught to recognise your lung cancer.

Dr. Sharmin Yaqin often uses the analogy of a detective being shown a photograph of a specific suspect versus being told to look for “anyone suspicious.” The first detective is far more effective. Dendritic Cell Therapy gives your immune system the photograph.

What Conditions Is Dendritic Cell Therapy Used For?

At Denvax, we have used Dendritic Cell Therapy across a wide range of solid tumour cancers, including:

• Lung cancer (non-small cell and small cell)
• Breast cancer (including triple-negative breast cancer where targeted therapy options are limited)
• Colorectal / Colon cancer
• Prostate cancer
• Liver cancer (hepatocellular carcinoma)
• Kidney cancer (renal cell carcinoma)
• Cervical cancer
• Ovarian cancer
• Brain tumours (glioblastoma and others)
• Head and neck cancers
• Pancreatic cancer
• Melanoma
• Stomach cancer
• Bladder cancer

It is also used in some blood cancers, particularly where solid organ involvement is present.

Dendritic Cell Therapy is not universally appropriate for every patient with these conditions — it depends on disease stage, immune system status, prior treatment history, and specific tumour biology. We evaluate every patient individually before making a recommendation.

—

The Treatment Protocol: What to Expect Step by Step

Step 1: Consultation and Evaluation

Your first appointment with Dr. Khan and Dr. Yaqin involves a comprehensive review of your medical history, current investigations, pathology reports, and scans. We assess your immune system baseline and discuss whether Dendritic Cell Therapy is appropriate for your specific situation. If it is, we explain the full protocol.

Step 2: Blood Collection

We collect a sample of your blood — a straightforward venous draw, similar to any blood test. This is used to isolate the monocytes that will be developed into dendritic cells.

Step 3: Laboratory Processing

Your monocytes are taken to our specialised laboratory where, over approximately one week, they are matured into fully active dendritic cells and educated using tumour antigens specific to your cancer. This step is done under strictly controlled conditions to ensure quality and potency.

Step 4: Infusion

The prepared dendritic cells are infused back into your body. The infusion process is straightforward — similar to a standard intravenous infusion. Most patients tolerate it very well. There is no sedation required.

Step 5: Monitoring and Response Assessment

We monitor immune response markers to assess how your immune system is responding. Imaging at appropriate intervals shows whether tumour burden is changing. If needed, additional cycles of therapy are planned.

A typical initial protocol at Denvax involves multiple infusion cycles over several months. The exact protocol is tailored to your cancer type and how you respond to initial treatment.

Side Effects: What to Expect

One of the most frequently asked questions we receive is about side effects. Compared to chemotherapy and radiation therapy, Dendritic Cell Therapy has a significantly milder side effect profile. Because we are using your own cells, the risk of rejection or severe immune reactions is minimal.

Commonly reported effects include:
– Mild flu-like symptoms for 24–48 hours after infusion (fatigue, mild fever, muscle ache) — this is a sign of immune activation and is generally a positive signal
– Mild redness or tenderness at the injection site in some protocols
– Fatigue during the treatment course

Severe adverse effects are uncommon. This makes Dendritic Cell Therapy particularly relevant for patients who have already experienced the hardship of heavy chemotherapy and are looking for an approach that does not further compromise quality of life.

How Does Dendritic Cell Therapy Combine With Other Treatments?

Dendritic Cell Therapy does not have to be used alone. In many patients, we design combination protocols that use the strengths of multiple approaches:

With low-dose chemotherapy: Low-dose chemo can increase tumour antigen shedding, which can enhance the ability of dendritic cells to identify and present tumour markers. Strategic combination can produce results superior to either treatment alone.

With checkpoint inhibitors: Drugs like pembrolizumab or nivolumab remove the “shields” cancer cells use to hide from immune cells. Combining them with Dendritic Cell Therapy — which is actively generating an immune response — can significantly increase effectiveness.

With targeted therapy: For cancers with specific driver mutations (EGFR, ALK, HER2, BRAF), targeted therapy can be used alongside immunotherapy.

With radiation: Radiation has an “abscopal effect” — when used strategically alongside immunotherapy, the local inflammation caused by radiation can enhance the systemic immune response being generated by the therapy.

Every protocol we design at Denvax is based on what the published evidence supports for the specific cancer being treated.

What Results Have Denvax Patients Experienced?

We have treated patients with Dendritic Cell Therapy who:

– Had been told by other oncologists that treatment options were exhausted
– Were Stage 3 or Stage 4 at the time of beginning treatment
– Had previously received chemotherapy and were seeking a less toxic ongoing approach
– Wanted to use immunotherapy preventively alongside conventional treatment from the start

The outcomes we have observed include tumour reduction, stabilisation of disease (preventing further spread), improved quality of life, and in a number of cases, complete or near-complete remissions in patients who began treatment with very advanced disease.

We do not make promises about outcomes — cancer is complex and individual. But we can say that many patients who expected months received years.

Dendritic Cell Therapy Cost in India — 2026

Dendritic Cell Therapy in India is substantially more accessible in cost terms than in Western countries, where the same treatment can cost tens of thousands of dollars. At Denvax, we have worked to make this treatment available to Indian patients at a cost that is realistic.

The cost of a Dendritic Cell Therapy protocol at Denvax depends on:
– The number of infusion cycles in your protocol
– Whether combination treatment is being used
– Ancillary testing and monitoring requirements

We provide a transparent, itemised cost breakdown at your initial consultation. We do not hide costs or apply surprise charges. For a personalised estimate based on your specific case, please book a consultation.

Frequently Asked Questions

Q: How is Dendritic Cell Therapy different from other types of immunotherapy?
A: Most immunotherapy approaches (checkpoint inhibitors, CAR-T therapy) work by broadly activating or genetically modifying immune cells. Dendritic Cell Therapy is unique in that it uses your own unmodified cells, educated with information specific to your cancer. It is highly personalised and has a low risk of the severe immune overreaction that can occur with some other immunotherapy types.

Q: Is Dendritic Cell Therapy approved in India?
A: Dendritic Cell Therapy is offered at licensed centres in India. At Denvax, our protocols follow international standards and our laboratory processes adhere to required quality standards. We recommend all patients ask any centre about their laboratory accreditation and protocol standards before proceeding.

Q: How many sessions of Dendritic Cell Therapy will I need?
A: This varies by patient. A standard initial protocol typically involves a series of infusions over several months. We assess response and design ongoing treatment plans based on how your immune system and tumour are responding.

Q: Can Dendritic Cell Therapy be used if I have already had chemotherapy?
A: Yes, in many cases. Chemotherapy can suppress immune function, so we evaluate your immune system baseline carefully. In patients where the immune system has capacity, Dendritic Cell Therapy can be highly effective even after prior chemotherapy.

Q: Can Dendritic Cell Therapy prevent cancer recurrence?
A: This is an area of active investigation. There is evidence suggesting that immunotherapy, including Dendritic Cell Therapy, may reduce the risk of recurrence by maintaining immune surveillance. Some patients use it as a maintenance therapy after achieving remission.

Q: Is Dendritic Cell Therapy painful?
A: The treatment itself involves a standard blood draw and an intravenous infusion. The infusion is not painful. Some patients experience mild flu-like symptoms for 24–48 hours after infusion, which typically resolve without intervention.

Ready to Explore Dendritic Cell Therapy?

If you are living with cancer — or supporting a family member who is — we invite you to speak with us. At Denvax, every consultation with Dr. Khan and Dr. Yaqin is a genuine conversation about your specific situation. We will tell you honestly whether Dendritic Cell Therapy is the right approach for you, what the protocol would look like, and what you can realistically expect.

Book Your Consultation at Denvax →

Dr. Jamal A. Khan is a pioneer of Dendritic Cell Therapy in India and founder of Denvax. Dr. Sharmin Yaqin is Director of Denvax India with extensive clinical experience in immunotherapy protocols. Denvax has been providing personalised cancer immunotherapy to patients across India for over a decade.